To validate the utility of our model as a platform for the development of nonsense mutant TP53-targeted anti-cancer drugs, we showed that the well-known readthrough inducer G418 could restore expression of full-length and functional p53 in T-lymphoma cell lines derived from Trp53R210X/R210X mice. The gene discussed is TP53; the disease is cancer.